2. Academic Validation
  3. RIPK1 Drives JAK1-STAT3 Signaling to Promote CXCL1-Mediated Neutrophil Recruitment in Sepsis-Induced Lung Injury

RIPK1 Drives JAK1-STAT3 Signaling to Promote CXCL1-Mediated Neutrophil Recruitment in Sepsis-Induced Lung Injury

  • Adv Sci (Weinh). 2025 Sep 15:e07123. doi: 10.1002/advs.202507123.
Hao Sun 1 2,  Xiya Li 1 2,  Shenjia Gao 1 2,  Yi Jiang 1 2,  Xinyi Wu 1 2,  Zhaoyuan Chen 1 2,  Han Wu 1 2,  Qing Hua 1 2,  Rui Zu 3,  Huaijiang Xiang 3,  Ronen Ben-Ami 4,  Changhong Miao 1 2,  Li Tan 3,  Ying Li 3,  Jun Wang 5,  Wankun Chen 1 2 6 7
Affiliations

Affiliations

  • 1 Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
  • 2 Shanghai Key laboratory of Perioperative Stress and Protection, Shanghai, 200032, China.
  • 3 Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 201210, China.
  • 4 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel.
  • 5 Department of Integrative Medicine and Neurobiology, School of Basic Medical Science, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, 200032, China.
  • 6 Department of Anesthesiology, Shanghai Geriatric Medical Center, Shanghai, 201104, China.
  • 7 Department of Anesthesiology, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, 201700, China.
PMID: 40953301 DOI: 10.1002/advs.202507123
Abstract

Sepsis-induced lung injury, characterized by unregulated inflammation and impaired alveolar epithelial integrity, significantly contributes to sepsis-related mortality. Although receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is critical in regulating Necroptosis and inflammation, its precise contribution to sepsis-induced lung injury remains poorly understood. In this study, selective activation of RIPK1 in type II alveolar epithelial cells (AECs) is observed during sepsis. CXCL1 is identified as a critical downstream target of RIPK1 through integrative transcriptomic and proteomic analyses. Mechanistically, RIPK1 interacts with JAK1 to induce STAT3 phosphorylation, facilitate its nuclear translocation, and promote its binding to the Cxcl1 promoter, thereby upregulating its expression and driving excessive neutrophil recruitment. Genetic or pharmacological inhibition of RIPK1 attenuated CXCL1 production, neutrophil infiltration, and alveolar damage, improving survival in septic mice. Compound 62, a selective RIPK1 Inhibitor, has demonstrated efficacy in attenuating systemic inflammatory cascades, preserving epithelial barrier integrity, and improving survival rates in mice. These findings establish RIPK1 as a therapeutic target in sepsis-induced lung injury and redefine alveolar epithelial cells as positive contributors to inflammatory amplification. This work advances precision strategies to mitigate sepsis-induced lung injury, addressing a critical unmet need in critical care medicine.

Keywords

CXCL1; JAK1‐STAT3; RIPK1; alveolar epithelial cells; neutrophil; sepsis‐induced lung injury; signaling.

Figures
Products
Inhibitors & Agonists
Other Products